Piramal Pharma Limited has received a permanent revocation of closure directions for its Dahej manufacturing site from the Gujarat Pollution Control Board (GPCB). The order was issued under Section 33A of the Water (Prevention and Control of Pollution) Act, 1974, concluding a regulatory proceeding initiated earlier in 2026.
Piramal Pharma Limited had previously informed exchanges on February 4, 12, and 14, 2026 about the initial closure directions from GPCB. The Dahej facility is located at Plot No. D-2/11/A/1, GIDC Dahej, Taluka Vagra, District Bharuch, Gujarat. GPCB had granted an interim revocation of the closure directions before issuing the permanent revocation order.
Operations at the Dahej site continue in the normal course following the permanent revocation. Piramal Pharma Limited stated its commitment to maintaining the highest standards of environmental compliance.
The disclosure was made to BSE Limited and the National Stock Exchange of India Limited under Regulation 30 of the SEBI Listing Regulations. The BSE scrip code for Piramal Pharma Limited is 543635 and the NSE symbol is PPLPHARMA. Maneesh Sharma, Company Secretary and Compliance Officer, signed the filing on June 3, 2026.
Piramal Pharma Limited is a pharmaceutical company publicly traded on both BSE and NSE. The permanent revocation order brings the regulatory process to a close, with GPCB withdrawing the closure directive that had been in place since February 2026.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.